BPC-157 is not approved for therapeutic use by the United States Food and Drug Administration (FDA) or any comparable regulatory agency, and its use in sport is banned by the World Anti-Doping Agency (WADA) [7]
Options for managing tolerance include a brief dose reduction for 4 to 8 weeks ("drug holiday" at a lower dose, not complete cessation), lifestyle optimization to maximize the medication effect, evaluation for other contributing factors (thyroid function, cortisol, sleep quality, medication interactions), and consideration of adding a complementary compound to address specific aspects of the plateau
A polymorphism in the interleukin-4 receptor affects the ability of interleukin-4 to regulate Th17 cells: a possible immunoregulatory mechanism for genetic control of the severity of rheumatoid arthritis
Acknowledgements The authors appreciate the support from Laboratory of Integrative Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, Peoples Republic of China and funding from the National Natural Science Foundation of China (No
Strict liability mandates that athletes are responsible for the detection of any prohibited substance in their bodies, irrespective of intent or origin
